Pharmacist Involvement with Core Measures enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) therapy for patients with left ventricular (LV) systolic dysfunction or documentation of contraindication to such therapy, and (4) smoking cessation advice/counseling. 2 To be included in the HF core measure, a patient must be admitted to the hospital with a principal diagnosis of HF. Several practices must take place to meet these standards and be in compliance with the HF core measure criteria. For the discharge instruction criteria, patients must receive instructions regarding specifi c symptoms that warrant treatment, diet and weight management, and activity level. Patients must also be given complete discharge medication instructions that include documentation of home medications and new medications to be continued following discharge. LV systolic function must be recorded in the patient's medical record as an ejection fraction (EF). Patients with LV systolic dysfunction and an EF less than 40% should receive ACEI or ARB therapy, unless a contraindication is documented. Finally, patients who smoke must be given advice or counseling on smoking cessation. All elements of these 4 criteria must be clearly documented in the patient's medical record.
TJC recognizes pharmacists as health care professionals who aid in the implementation of core measures. Beginning in 2008, TJC allowed documentation of LV systolic function and contraindications to ACEI or ARB therapy by a pharmacist to meet the HF core measure criteria. 2 Further, pharmacists can aid in the medication reconciliation process to help ensure that patients receive a complete list of discharge medications. 3 With this authorization from TJC, pharmacists could potentially have a discrete role in achieving compliance with the HF core measure.
The OU Medical Center is a 361-bed adult academic teaching institution serving central Oklahoma. Historically, HF core measures have largely been managed by OU Medical Center nursing leadership and staff. Rates of compliance with the HF core measure at OU Medical Center from January 2009 to March 2009 were as follows: 80.6% of HF patients were given complete discharge instructions, 100% had documentation of LV systolic function, 93.3% were prescribed an ACEI or ARB for LV systolic dysfunction or a contraindication to therapy was documented, and 100% were provided smoking cessation counseling. At that time, a nurse leader, the medical staff, and nursing staff were ultimately responsible for compliance to the core measure for each patient with a principal diagnosis of HF. The nurse leader worked to ensure documentation of LV systolic function, appropriate drug therapy (if indicated for an EF <40%), or documentation of a contraindication to therapy. Prior to discharge, home medication orders were completed by the physician. Then, the nursing staff transcribed the medication orders to a discharge instruction sheet that was given to the patient, which also included counseling on diet and weight management, activity level, and specifi c symptoms that warrant further treatment. Written smoking cessation counseling for patients with a smoking history was also included on the discharge instruction sheet. Final diagnostic codes were assigned after discharge. A quality nurse analyst reviewed each patient chart coded with a principal diagnosis of HF for compliance with the HF core measure and entered compliance status (compliant vs noncompliant) into a database. This information is submitted to and publicly reported by the CMS and the US Department of Health and Human Services (http://www.
hospitalcompare.hhs.gov).
In Fall 2009, opportunities for improvement in compliance with 2 of the HF core measure criteria were identifi ed: proportion of patients receiving complete discharge instructions and an ACEI/ARB for LV systolic dysfunction. Therefore, a pharmacist joined the nurse leader and patient care team (nurses and physicians) to help improve compliance to the HF core measure. The purpose of this study was to measure the impact of pharmacist involvement at discharge on compliance with the overall HF core measure.
METHODS

Study Design
This was a prospective study conducted at discharge on patients with a principal diagnosis of HF from January 2010 through March 2010. Patients between the ages of 18 and 100 years admitted with an initial principal diagnosis of HF were included. Of note, because the fi nal coding of diagnosis occurs after patient discharge, all patients with a preliminary diagnosis code (ie, clinical suspicion of HF) were included for the initial chart review. Patients were excluded if they were transferred to other facilities prior to discharge. The study protocol was reviewed and approved by the local institutional review board. Informed consent was waived on the basis that the research involved no more than minimal risk to the participants.
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Intervention
The pharmacist was notifi ed by the nurse of patients with HF who were being discharged. The pharmacist performed chart reviews 1 to 3 hours prior to discharge to evaluate compliance with the HF core measure. The pharmacist then intervened as needed based on this chart review to ensure compliance with the HF core measure. The specifi c interventions are defi ned in Table 1 .
Outcomes Measured
The primary outcome was HF core measure compliance rates with pharmacist involvement at discharge compared to rates during the same 3-month period during the previous year (January 2009 to March 2009, without pharmacist involvement). Electronic medical records and hardcopy medical charts served as principal data sources. The quality nurse analyst reported compliance rates to study personnel for statistical analysis. Compliance rates were then collected as nominal variables and compared using the chi-square test.
RESULTS
During the study period (January 2010 to March 2010), 92 patients were admitted with clinical suspicion of HF. Of these 92 patients, the pharmacist reviewed 45 patient charts at discharge (49%). Thirty-one of the 45 patients reviewed by the pharmacist were excluded from fi nal analysis due to the correction of the coded medical diagnosis after discharge, leaving 14 patients for fi nal analysis (14/45; 31%) (Figure 1) .
The compliance rates to the TJC HF core measure with pharmacist involvement from January 2010 to March 2010 were reported as follows: 78.9% were given complete discharge instructions, 100% had documentation of LV systolic function, 100% were prescribed an ACEI or ARB for LV systolic dysfunction, and 100% were provided smoking cessation counseling. No difference in these rates was found compared to the control period of January 2009 to March 2009 without pharmacist involvement (P = .39) ( Table 2) . Note: ACEI = angiotensin-converting enzyme inhibitor; ARB = angiotensin receptor blocker; EF = ejection fraction; LV = left ventricular.
a Examples of medication discrepancies identifi ed and resolved: therapeutic duplication, medication omission, incorrect dose and/or interval, unintended drug continuation/discontinuation.
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Five of the 14 (36%) patients reviewed by the pharmacist were compliant with all 4 criteria of the HF core measure; therefore, no intervention was necessary. The pharmacist performed interventions on the remaining 9 patients, and the types of interventions are summarized in Table 1 . The majority of interventions (77.8%) were due to medication discrepancies within the discharge instructions that were found during medication reconciliation. The most common medication discrepancy was the omission of medications from the physician discharge orders to the discharge instructions at the time of transcription.
Discussion
Pharmacist involvement did not translate into improved compliance with the HF core measure. There were no additional process changes that would have affected the results during or between study periods. The small sample size of patients included in the fi nal analysis may have impacted these data. In spite of this limitation, the study provided insight into barriers that exist to meeting the core measure and into the feasibility of utilizing pharmacists to improve adherence.
Barriers to meeting the core measure manifested primarily in discharge instructions. Completeness of discharge instructions was the lowest area of compliance during both timeframes, with complete discharge medication instructions being the principal component of noncompliance. Physicians often dictated discharge summaries after patients were released from the hospital, and the dictated summaries were often inconsistent with the discharge orders provided for transcription at the time of discharge. Medications were not reconciled between the original discharge orders and dictated summaries, because the dictation was done after discharge; therefore, medications were often omitted from the patient's discharge instructions. Such discrepancies are unlikely to be avoided without a change in this process. These fi ndings are similar to a study in which compliance with discharge instructions remained lower than anticipated because of documentation issues within the medication reconciliation process. 4 Changes in the discharge medication transcription process at our institution are currently in process to address this systematic problem.
Another barrier to compliance was the lack of a streamlined process at discharge. During the study, 3 people were involved in the review and reporting process for HF patients (nurse leader, quality nurse Evaluation of LV systolic function 100 100
Given ACEI/ARB for LV dysfunction or documentation of contraindication to therapy
100
Smoking cessation advice/counseling 100 100
Note: ACEI = angiotensin-converting enzyme inhibitor; ARB = angiotensin receptor blocker; HF = heart failure; LV = left ventricular.
a P = .39 for comparison of 2 time periods overall (all 4 criteria combined).
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analyst, and pharmacist) as described earlier. With so many health care professionals involved, notifi cation of HF patients being discharged was inconsistent and the pharmacist was not always notifi ed of discharge patients for review. Also, the manpower needed for review of all HF patients at the time of discharge was greater than what one pharmacist could accommodate; one pharmacist was allocated 30% time to assume this responsibility. This appeared to be insufficient, because the pharmacist was only able to review half of the patients (45/92) with a clinical suspicion of HF. Furthermore, since the pharmacist relied on preliminary diagnosis codes (ie, clinical suspicion of HF) to identify HF patients, the majority of the pharmacist's effort was spent on review of patients without a fi nal primary diagnosis of HF. The feasibility of routinely including pharmacists at the point of discharge for each HF patient would likely require multiple pharmacists dedicated to evaluating compliance with the core measure, including evenings and weekends. Given the high baseline compliance with the HF core measure, the added value of additional health care professionals is uncertain. The current process has been streamlined such that one person, a HF quality nurse coordinator (0.5 full-time equivalent) is solely responsible for the review HF patients and compliance to TJC HF core measure. Prior to this study, a HF quality nurse coordinator was not part of our institution's health care team. This has led to a more effi cient approach that focuses on HF patients from admission to discharge, ultimately reducing unnecessary review and improving communication.
Future research should focus on interventions to improve the medication reconciliation process for HF patients. A study is currently evaluating the role of pharmacists in the discharge medication reconciliation process and the reduction of unintentional medication errors at discharge. 5 This trial may provide insight into the value of pharmacists in the medication reconciliation process, but future studies should focus on the role of pharmacists in the medication reconciliation process at discharge for HF patients and compliance with TJC HF core measure.
CONCLUSION
In this investigation, addition of a pharmacist to a multidisciplinary team did not improve compliance to TJC HF core measure. However, systematic issues contributing to noncompliance were identifi ed. Quality improvement measures are planned or in place to address these issues.
